Which drugs does patent 6,028,222 protect, and when does it expire?
Patent 6,028,222 protects OFIRMEV and is included in one NDA. There has been one Paragraph IV challenge on Ofirmev.
Protection for OFIRMEV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-nine patent family members in twenty-one countries.